Patrick Wood
Stock Analyst at Morgan Stanley
(2.32)
# 2,648
Out of 5,148 analysts
122
Total ratings
46.81%
Success rate
-0.24%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Maintains: Overweight | $48 → $52 | $46.45 | +11.95% | 2 | Mar 2, 2026 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $80 → $85 | $80.41 | +5.71% | 9 | Feb 5, 2026 | |
| BSX Boston Scientific | Maintains: Overweight | $130 → $118 | $75.85 | +55.57% | 8 | Feb 5, 2026 | |
| COO The Cooper Companies | Maintains: Equal-Weight | $76 → $83 | $82.62 | +0.46% | 7 | Dec 8, 2025 | |
| TMDX TransMedics Group | Maintains: Equal-Weight | $123 → $135 | $139.78 | -3.42% | 3 | Dec 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Equal-Weight | $17 → $23 | $24.69 | -6.84% | 6 | Dec 2, 2025 | |
| RXST RxSight | Maintains: Equal-Weight | $9 → $10 | $7.64 | +30.89% | 3 | Dec 2, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $56 → $51 | $23.29 | +118.98% | 4 | Dec 2, 2025 | |
| DXCM DexCom | Upgrades: Overweight | $63 → $75 | $72.11 | +4.01% | 10 | Dec 2, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $197 → $210 | $174.00 | +20.69% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $19 → $15 | $19.52 | -23.16% | 6 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $14 → $21 | $18.07 | +16.21% | 9 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $84 → $80 | $84.40 | -5.21% | 5 | Aug 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $276 → $295 | $246.27 | +19.79% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $75 → $81 | $86.27 | -6.11% | 9 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $80 → $103 | $73.28 | +40.56% | 5 | Jul 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $110 → $72 | $120.83 | -40.41% | 4 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $191 → $173 | $121.42 | +42.48% | 5 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $243.30 | +30.29% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $1.99 | +402.51% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $18.91 | +95.66% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $154.50 | - | 5 | Dec 11, 2017 |
Medline
Mar 2, 2026
Maintains: Overweight
Price Target: $48 → $52
Current: $46.45
Upside: +11.95%
GE HealthCare Technologies
Feb 5, 2026
Maintains: Equal-Weight
Price Target: $80 → $85
Current: $80.41
Upside: +5.71%
Boston Scientific
Feb 5, 2026
Maintains: Overweight
Price Target: $130 → $118
Current: $75.85
Upside: +55.57%
The Cooper Companies
Dec 8, 2025
Maintains: Equal-Weight
Price Target: $76 → $83
Current: $82.62
Upside: +0.46%
TransMedics Group
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $123 → $135
Current: $139.78
Upside: -3.42%
Tandem Diabetes Care
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $17 → $23
Current: $24.69
Upside: -6.84%
RxSight
Dec 2, 2025
Maintains: Equal-Weight
Price Target: $9 → $10
Current: $7.64
Upside: +30.89%
PROCEPT BioRobotics
Dec 2, 2025
Maintains: Overweight
Price Target: $56 → $51
Current: $23.29
Upside: +118.98%
DexCom
Dec 2, 2025
Upgrades: Overweight
Price Target: $63 → $75
Current: $72.11
Upside: +4.01%
Becton, Dickinson and Company
Dec 2, 2025
Maintains: Overweight
Price Target: $197 → $210
Current: $174.00
Upside: +20.69%
Dec 2, 2025
Maintains: Underweight
Price Target: $19 → $15
Current: $19.52
Upside: -23.16%
Dec 2, 2025
Upgrades: Overweight
Price Target: $14 → $21
Current: $18.07
Upside: +16.21%
Aug 21, 2025
Maintains: Equal-Weight
Price Target: $84 → $80
Current: $84.40
Upside: -5.21%
Aug 8, 2025
Maintains: Overweight
Price Target: $276 → $295
Current: $246.27
Upside: +19.79%
Jul 15, 2025
Maintains: Equal-Weight
Price Target: $75 → $81
Current: $86.27
Upside: -6.11%
Jul 15, 2025
Upgrades: Overweight
Price Target: $80 → $103
Current: $73.28
Upside: +40.56%
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $120.83
Upside: -40.41%
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $121.42
Upside: +42.48%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $243.30
Upside: +30.29%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $1.99
Upside: +402.51%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $18.91
Upside: +95.66%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $154.50
Upside: -